Andere talen RegeneRx Biopharmaceuticals, Inc.

Aandelen

RGRX

US75886X3061

Beurs gesloten - OTC Markets Andere beurzen 19:09:18 21-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,0014 ^USD	0,00%		0,00%	+16,67%

2023	RegeneRx Biopharmaceuticals, Inc. rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2023	CI
2023	RegeneRx Biopharmaceuticals, Inc. rapporteert winstresultaten voor het volledige jaar eindigend op 31 december 2022	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations	16-08-23
RegeneRx Receives Stockholder Approval for Reverse Stock Split	07-08-23
RegeneRx Biopharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K	07-08-23
RegeneRx To Extend Consent Solicitation Vote	01-08-23
RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A.	03-07-23
RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding	13-06-23
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
RegeneRx Biopharmaceuticals, Inc. - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical trial with RGN-259	14-04-23
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259	13-04-23
RegeneRx Issues Letter To Stockholders	11-04-23
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operation. (form 10-K)	11-04-23
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	11-04-23
RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	11-04-23
Thymosin Beta 4 Research Leads Toward Potential Future Anti-Aging Therapy	31-01-23
Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy	31-01-23
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy	03-01-23
Regenerx Biopharmaceuticals, Inc. Reports New Scientific Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy	03-01-23
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14-11-22
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14-11-22
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease	24-10-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen RegeneRx Biopharmaceuticals, Inc.

Aandelen

RGRX

US75886X3061

Andere talen

Filters